Atrial Fibrillation (AF)
Cardiovascular
2
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
NovartisAbelacimab
NovartisAbelacimab
BayerBAY2433334
AbbottAmulet™ 2 Left Atrial Appendage
Clinical Trials (4)
Total enrollment: 4,400 patients across 4 trials
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Start: Dec 2022Est. completion: Oct 20261,900 patients
Phase 3Recruiting
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Start: Feb 2021Est. completion: Dec 20281,287 patients
Phase 2Active Not Recruiting
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Start: Jan 2020Est. completion: Oct 2021755 patients
Phase 2Completed
Abbott Medical - VERITAS Study
Start: Nov 2024Est. completion: Sep 2027458 patients
N/AActive Not Recruiting
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr
Associate Regulatory Affairs Specialist
Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr
Business Development Manager, Post Transplant, Cardio Thoracic
Thermo Fisher Scientific
Remote
Yesterday
Director, Medical Affairs
Abbott
Germany - Hesse - Eschborn
Yesterday
Therapy Development Manager
Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 4,400 patients
4 companies competing in this space